SELLAS Life Sciences Group, Inc. (SLS) Tuesday said that its Phase 2 trial of SLS009 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) met all primary goals.
The Phase 2 study was designed to evaluate SLS009 in combination with venetoclax and azacitidine. The primary endpoint for the trial was overall response rate (ORR). The study exceeded target ORR of 20% with 44% response rate in patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR). Median Overall Survival (mOS) was 8.9 Months, which surpassed the historical median of 2.4 months.
The FDA has recommended SELLAS to include newly diagnosed, first-line AML patients in a study, that may support a New Drug Application. The company plans to initiate the study by the first quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.